Actively Recruiting
Mechanisms of Resistance to PSMA Radioligand Therapy
Led by University of California, San Francisco · Updated on 2026-03-18
125
Participants Needed
3
Research Sites
271 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
CONDITIONS
Official Title
Mechanisms of Resistance to PSMA Radioligand Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Starting treatment with Lutetium-based PSMA-targeted radioligand therapy
- Have a PSMA-positive lesion accessible for biopsy, preferably newly emerging metastatic lesions
- Able to tolerate stopping blood thinners like warfarin or aspirin for at least five days before biopsy
- Age 18 years or older
- Able to understand and willing to sign informed consent
You will not qualify if you...
- Have significant congenital or acquired bleeding disorders (e.g., von Wildebrand's disease)
- Unable to undergo additional study-related imaging procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
Actively Recruiting
2
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
3
Memorial Sloan Kettering
New York, New York, United States, 10065
Actively Recruiting
Research Team
M
Maya Aslam
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here